OVERLAP SYNDROME OF ALLERGIC CONTACT DERMATITIS AND ATOPIC DERMATITIS: FOCUS ON PATIENTS' QUALITY OF LIFE AND CLINICAL CASES
Introduction. The combination of atopic dermatitis (AD) with allergic contact dermatitis (ACD) or the occurrence of ACD on the background of AD has been called overlap syndrome. Due to the debilitating symptom complex, which includes itching, discomfort, pain, sleep disturbances and psychological di...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
State Institution of Science «Research and Practical Center of Preventive and Clinical Medicine» State Administrative Department
2025-04-01
|
| Series: | Клінічна та профілактична медицина |
| Subjects: | |
| Online Access: | https://cp-medical.com/index.php/journal/article/view/577 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Introduction. The combination of atopic dermatitis (AD) with allergic contact dermatitis (ACD) or the occurrence of ACD on the background of AD has been called overlap syndrome. Due to the debilitating symptom complex, which includes itching, discomfort, pain, sleep disturbances and psychological disorders, the overlap syndrome (OS) of ACD and AD has a significant negative impact on the quality of life.
Aim. To determine the effectiveness of integrating a sedative component into the treatment regimen of ACD and AD overlap syndrome in the context of impact on patients’ quality of life.
Materials and methods. Based at the Department of Dermatovenereology, Clinical and Laboratory Immunology of the Shupyk National Healthcare University of Ukraine, 68 patients with a confirmed diagnosis of AD and ACD overlap syndrome were treated. To assess the impact of the disease on the quality of life, the questionnaire "QLI-OS-AD/ACD-2024" was used.
Results. Assessment of the patients' quality of life showed that both in the study group, whose patients received a sedative complex of magnesium and melatonin in the OS ACD and AD management scheme, and in the control group, after the treatment, the quality of life indicators predictably improved. Treatment significantly increases the proportion of patients who assess the impact of the disease on their quality of life as "insignificant" and reduces the proportion of those who recognize the impact as "significant" or as one that brings "significant deterioration." The proportion of patients with anxiety in the study group decreased by half, and the proportion of patients with insomnia – by 41.0%; on the other hand, in the control group, patients with anxiety decreased by 21.1%, and the number of patients suffering from insomnia decreased by only 14.4%.
Conclusions. Integration of a sedative combination of magnesium, melatonin and vitamin B6 into the complex therapy regimen for OS ACD and AD leads to a more significant improvement in the quality of life of dermatological patients by reducing the manifestations of depression, anxiety and insomnia. The questionnaire "QLI-OS-AD/ACD-2024" allows the practicing physician to quickly and inexpensively assess the degree of impact of AD and ACD overlap syndrome on the patients’ quality of life. |
|---|---|
| ISSN: | 2616-4868 |